Erika Peverelli

Milan, 20122, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

The Role of Splicing Machinery as a Promising Potential Therapeutic Target for Pituitary Neuroendocrine Tumors (PitNETs).

The Role of Splicing Machinery as a Promising Potential Therapeutic Target for Pituitary Neuroendocrine Tumors (PitNETs).

Journal: Cancers

Published: June 04, 2026

Micromegaly: a distinct clinical entity? Insights from a monocentric cohort study.

Micromegaly: a distinct clinical entity? Insights from a monocentric cohort study.

Journal: Frontiers in endocrinology

Published: May 06, 2026

IGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis.

IGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis.

Journal: Cell communication and signaling : CCS

Published: February 18, 2026

Characterization of SF3B1 role in prolactin-secreting pituitary tumors.

Characterization of SF3B1 role in prolactin-secreting pituitary tumors.

Journal: Endocrine-related cancer

Published: December 15, 2025

Prevalence of somatic SF3B1R625H mutation in lactotroph tumours from a multi-centric cohort: a digital PCR-based study.

Prevalence of somatic SF3B1R625H mutation in lactotroph tumours from a multi-centric cohort: a digital PCR-based study.

Journal: European journal of endocrinology

Published: December 11, 2025

Biological targets and therapeutic strategies in the treatment of non-functioning pituitary tumors: state-of-the-art.

Biological targets and therapeutic strategies in the treatment of non-functioning pituitary tumors: state-of-the-art.

Journal: European journal of endocrinology

Published: December 02, 2025

Caspase-8 as a Candidate Mediator Associated with Everolimus Resistance in Neuroendocrine Tumors.

Caspase-8 as a Candidate Mediator Associated with Everolimus Resistance in Neuroendocrine Tumors.

Journal: Journal of molecular endocrinology

Published: November 27, 2025

Clinical predictors of outcome in advanced adrenocortical carcinoma: a multicenter international ENSAT study.

Clinical predictors of outcome in advanced adrenocortical carcinoma: a multicenter international ENSAT study.

Journal: European journal of endocrinology

Published: November 06, 2025

Pan-CDK and PLK1 inhibitors as a novel approach for targeted treatment of adrenocortical carcinomas.

Pan-CDK and PLK1 inhibitors as a novel approach for targeted treatment of adrenocortical carcinomas.

Journal: European journal of endocrinology

Published: October 16, 2025

The Cytoskeleton in Adrenal Physiology and Tumours: Functional Roles and Emerging Molecular Targets.

The Cytoskeleton in Adrenal Physiology and Tumours: Functional Roles and Emerging Molecular Targets.

Journal: International journal of molecular sciences

Published: September 11, 2025

Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma.

Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma.

Journal: Pharmacological research

Published: August 07, 2025

Retraction Note: High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells.

Retraction Note: High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells.

Journal: Oncogene

Published: July 28, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026